Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals

Dysregulation of complement activation causes a number of diseases, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. These conditions can be treated with monoclonal antibodies (mAbs) that bind to the complement component C5 and prevent formation of the membrane a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ispasanie, Emma, Muri, Lukas, Schubart, Anna, Thorburn, Christine, Zamurovic, Natasa, Holbro, Thomas, Kammüller, Michael, Pluschke, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531814/
https://www.ncbi.nlm.nih.gov/pubmed/34691058
http://dx.doi.org/10.3389/fimmu.2021.747594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531814/
https://www.ncbi.nlm.nih.gov/pubmed/34691058
http://dx.doi.org/10.3389/fimmu.2021.747594

Ejemplares similares